Pfizer (NYSE:PFE) Stock Price Down 0.6% – Should You Sell?

Pfizer Inc. (NYSE:PFE)’s share price traded down 0.6% during mid-day trading on Wednesday . The company traded as low as $24.81 and last traded at $24.94. 8,742,763 shares traded hands during trading, a decline of 77% from the average session volume of 38,278,762 shares. The stock had previously closed at $25.10.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Citigroup started coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Trading Down 1.0 %

The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $140.77 billion, a P/E ratio of 33.70, a P/E/G ratio of 0.79 and a beta of 0.67. The firm has a 50 day simple moving average of $28.45 and a 200 day simple moving average of $28.63.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the business earned ($0.17) earnings per share. Pfizer’s revenue was up 31.2% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.76%. Pfizer’s payout ratio is currently 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Olistico Wealth LLC bought a new position in Pfizer during the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC purchased a new stake in Pfizer in the second quarter worth $29,000. Gladius Capital Management LP boosted its holdings in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares in the last quarter. Quarry LP bought a new position in Pfizer in the 2nd quarter worth $31,000. Finally, Financial Connections Group Inc. purchased a new stake in shares of Pfizer in the 2nd quarter worth about $34,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.